Abstract
While asthma is an inflammatory disorder of the airways involving mediators released from mast cells and eosinophils, inflammation alone is insufficient to explain the chronic nature of the disease. Recent progress in the understanding of disease pathogenesis has revealed that airway remodeling, which is at least in part due to an excess of extracellular matrix (ECM) deposition in the airway wall, plays a significant role in airflow obstruction. Matrix metalloproteinases (MMPs) have been suggested to be the major proteolytic enzymes to induce airway remodeling in asthma and COPD. It has been widely accepted that different inflammatory processes are involved in asthma and COPD with different inflammatory cells, mediators, and responses to treatments. Despite these different processes, airflow obstruction and airway remodeling characterize these two diseases. MMP-2 and -9 have been reported to be involved in the pathogenesis of airway remodeling in both diseases and MMP-12, in addition to these MMPs, in the pathogenesis of COPD.
In this review, we discuss the current views on the role of MMPs in the pathogenesis of bronchial asthma and COPD. Anti-MMP therapy could theoretically be useful to prevent airway remodeling in asthma and COPD. However, to date no clinical data are available regarding the efficacy of anti-MMP therapies in the treatment of patients with asthma and COPD.
Similar content being viewed by others
References
Barnes PJ. Pathophysiology of asthma. Br J Clin Pharmacol 1996; 42(1): 3–10
Thompson AB, Daughton D, Robbins RA, et al. Intraluminal airway inflammation in chronic bronchitis: characterization and correlation with clinical parameters. Am Rev Respir Dis 1989; 140(6): 1527–37
Roberts CR, Walker DC, Schellenberg RR. Extracellular matrix. Clin Allergy Immunol 2002; 16: 143–78
Albini A. Tumor and endothelial cell invasion of basement membranes: the matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res 1998; 4(3): 230–41
Gipson IK, Inatomi T. Extracellular matrix and growth factors in corneal wound healing. Curr Opin Ophthalmol 1995; 6(4): 3–10
Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990; 6(4): 121–5
Friedl P, Brocker EB. The biology of cell locomotion within three-dimensional extracellular matrix. Cell Mol Life Sci 2000; 57(1): 41–64
Wilson JW, Li X, Pain MC. The lack of distensibility of asthmatic airways. Am Rev Respir Dis 1993; 148(3): 806–9
Ohnishi K, Takagi M, Kurokawa Y, et al. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest 1998; 78(9): 1077–87
Wiggs BR, Bosken C, Pare PD, et al. A model of airway narrowing in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 145(6): 1251–8
Torii K, Iida K, Miyazaki Y, et al. Higher concentrations of matrix metalloproteinases in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome. Am J Respir Crit Care Med 1997; 155(1): 43–6
Carney DE, McCann UG, Schiller HJ, et al. Metalloproteinase inhibition prevents acute respiratory distress syndrome. J Surg Res 2001; 99(2): 245–52
Prikk K, Maisi P, Pirila E, et al. In vivo collagenase-2 (MMP-8) expression by human bronchial epithelial cells and monocytes/macrophages in bronchiectasis. J Pathol 2001; 194(2): 232–8
Hayashi T, Stetler-Stevenson WG, Fleming MV, et al. Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis. Am J Pathol 1996; 149(4): 1241–56
Liotta LA, Rao CN, Barsky SH. Tumor invasion and the extracellular matrix. Lab Invest 1983; 49(6): 636–49
Cox G, Jones JL, O’Byrne KJ. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 2000; 6(6): 2349–55
Galligioni E, Ferro A. Angiogenesis and antiangiogenic agents in non-small cell lung cancer. Lung Cancer 2001; 34Suppl. 4: 3–7
Phan SH, Thrall RS, Ward PA. Bleomycin-induced pulmonary fibrosis in rats: biochemical demonstration of increased rate of collagen synthesis. Am Rev Respir Dis 1980; 121(3): 501–6
Caughey GH. Chairman’s summary: mechanisms of airway remodeling. Am J Respir Crit Care Med 2001; 164 (10 Pt 2): S26–7
ten Brinke A, Grootendorst DC, Schmidt JT, et al. Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol 2002; 109(4): 621–6
Cutz E, Levison H, Cooper DM. Ultrastructure of airways in children with asthma. Histopathology 1978; 2(6): 407–21
Boulet LP, Laviolette M, Turcotte H, et al. Bronchial subepithelial fibrosis correlates with airway responsiveness to methacholine. Chest 1997; 112(1): 45–52
Ornstein DL, Cohn KH. Balance between activation and inhibition of matrix metalloproteinase-2 (MMP-2) is altered in colorectal tumors compared to normal colonic epithelium. Dig Dis Sci 2002; 47(8): 1821–30
Rajah R, Katz L, Nunn S, et al. Insulin-like growth factor binding protein (IGFBP) proteases: functional regulators of cell growth. Prog Growth Factor Res 1995; 6(2–4): 273–84
Rajah R, Nachajon RV, Collins MH, et al. Elevated levels of the IGF-binding protein protease MMP-1 in asthmatic airway smooth muscle. Am J Respir Cell Mol Biol 1999; 20(2): 199–208
Hoshino M, Nakamura Y, Sim J, et al. Bronchial subepithelial fibrosis and expression of matrix metalloproteinase-9 in asthmatic airway inflammation. J Allergy Clin Immunol 1998; 102(5): 783–8
Yao PM, Lemjabbar H, D’Ortho MP, et al. Balance between MMP-9 and TIMP-1 expressed by human bronchial epithelial cells: relevance to asthma. Ann N Y Acad Sci 1999; 878: 512–4
Ohno I, Ohtani H, Nitta Y, et al. Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation. Am J Respir Cell Mol Biol 1997; 16(3): 212–9
Dahlen B, Shute J, Howarth P. Immunohistochemical localisation of the matrix metalloproteinases MMP-3 and MMP-9 within the airways in asthma. Thorax 1999; 54(7): 590–6
Holz O, Jorres RA, Magnussen H. Monitoring central and peripheral airway inflammation in asthma. Respir Med 2000; 94Suppl. D: S7–12
Vignola AM, Riccobono L, Mirabella A, et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998; 158(6): 1945–50
Johnson S, Knox A. Autocrine production of matrix metalloproteinase-2 is required for human airway smooth muscle proliferation. Am J Physiol 1999; 277 (6 Pt 1): L1109–17
Legrand C, Polette M, Tournier JM, et al. uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial epithelial cell migration. Exp Cell Res 2001; 264(2): 326–36
Corry DB, Rishi K, Kanellis J, et al. Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency. Nat Immunol 2002; 3(4): 347–53
Lemjabbar H, Gosset P, Lamblin C, et al. Contribution of 92 kDa gelatinase/type IV collagenase in bronchial inflammation during status asthmaticus. Am J Respir Crit Care Med 1999; 159 (4 Pt 1): 1298–307
Suzuki R, Kato T, Miyazaki Y, et al. Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in sputum from patients with bronchial asthma. J Asthma 2001; 38(6): 477–84
Belleguic C, Corbel M, Germain N, et al. Increased release of matrix metalloproteinase-9 in the plasma of acute severe asthmatic patients. Clin Exp Allergy 2002; 32(2): 217–23
Tanaka H, Miyazaki N, Oashi K, et al. Sputum matrix metalloproteinase-9: tissue inhibitor of metalloproteinase-1 ratio in acute asthma. J Allergy Clin Immunol 2000; 105(5): 900–5
Mautino G, Oliver N, Chanez P, et al. Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics. Am J Respir Cell Mol Biol 1997; 17(5): 583–91
Kelly EA, Busse WW, Jarjour NN. Increased matrix metalloproteinase-9 in the airway after allergen challenge. Am J Respir Crit Care Med 2000; 162 (3 Pt 1): 1157–61
Rajah R, Nunn SE, Herrick DJ, et al. Leukotriene D4 induces MMP-1, which functions as an IGFBP protease in human airway smooth muscle cells. Am J Physiol 1996; 271 (6 Pt 1): L1014–22
Schwingshackl A, Duszyk M, Brown N, et al. Human eosinophils release matrix metalloproteinase-9 on stimulation with TNF-alpha. J Allergy Clin Immunol 1999; 104(5): 983–9
Mautino G, Henriquet C, Jaffuel D, et al. Tissue inhibitor of metalloproteinase-1 levels in bronchoalveolar lavage fluid from asthmatic subjects. Am J Respir Crit Care Med 1999; 160(1): 324–30
Zheng T, Zhu Z, Wang Z, et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest 2000; 106(9): 1081–93
Lim S, Roche N, Oliver BG, et al. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers: regulation by interleukin-10. Am J Respir Crit Care Med 2000; 162 (4 Pt 1): 1355–60
Robinson SC, Scott KA, Balkwill FR. Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha. Eur J Immunol 2002; 32(2): 404–12
Kikuchi K, Kadono T, Furue M, et al. Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. J Invest Dermatol 1997; 108(3): 281–4
Kikuchi K, Kubo M, Sato S, et al. Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis. J Am Acad Dermatol 1995; 33(6): 973–8
Bosse M, Chakir J, Rouabhia M, et al. Serum matrix metalloproteinase-9: tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma. Am J Respir Crit Care Med 1999; 159(2): 596–602
Hoshino M, Takahashi M, Takai Y, et al. Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J Allergy Clin Immunol 1999; 104 (2 Pt 1): 356–63
Lee YC, Lee HB, Rhee YK, et al. The involvement of matrix metalloproteinase-9 in airway inflammation of patients with acute asthma. Clin Exp Allergy 2001; 31(10): 1623–30
Nuovo GJ, MacConnell PB, Simsir A, et al. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 1995; 55(2): 267–75
Kallakury BV, Karikehalli S, Haholu A, et al. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 2001; 7(10): 3113–9
O-charoenrat P, Rhys-Evans PH, Eccles SA. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2001; 127(7): 813–20
Giannelli G, Bergamini C, Marinosci F, et al. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 2002; 97(4): 425–31
Yoshizaki T, Maruyama Y, Sato H, et al. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer 2001; 95(1): 44–50
Levitt NC, Eskens FA, O’Byrne KJ, et al. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 2001; 7(7): 1912–22
Nemunaitis J, Cox J, Hays S, et al. Prognostic role of K-ras in patients with progressive colon cancer who received treatment with Marimastat (BB2516). Cancer Invest 2000; 18(3): 185–90
Kumagai K, Ohno I, Okada S, et al. Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. J Immunol 1999; 162(7): 4212–9
Lee YC, Song CH, Lee HB, et al. A murine model of toluene diisocyanate-induced asthma can be treated with matrix metalloproteinase inhibitor. J Allergy Clin Immunol 2001; 108(6): 1021–6
Trifilieff A, Walker C, Keller T, et al. Pharmacological profile ofPKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in models of airway inflammation. Br J Pharmacol 2002; 135(7): 1655–64
Snider GL, Kleinerman J, Thurlbeck WM, et al. The definition of emphysema. Report of a National Heart, Lung, and Blood Institute, Division of Lung Diseases workshop. Am Rev Respir Dis 1985; 132(1): 182–5
Laurell CB, Erikson S. The electrophoretical alpha-1-globulin pattern of serum in alpha-1-antitrypsin deficiency. Scand J Clin Lab Invest 1963; 15: 132–40
Janoff A, Sloan B, Weinbaum G, et al. Experimental emphysema induced with purified human neutrophil elastase: tissue localization of the instilled protease. Am Rev Respir Dis 1977; 115(3): 461–78
Finlay GA, O’Donnell MD, O’Connor CM, et al. Elastin and collagen remodeling in emphysema: a scanning electron microscopy study. Am J Pathol 1996; 149(4): 1405–15
D’Armiento J, Dalai SS, Okada Y, et al. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell 1992; 71(6): 955–61
Hautamaki RD, Kobayashi DK, Senior RM, et al. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997; 277(5334): 2002–4
Meshi B, Vitalis TZ, Ionescu D, et al. Emphysematous lung destruction by cigarette smoke: the effects of latent adenoviral infection on the lung inflammatory response. Am J Respir Cell Mol Biol 2002; 26(1): 52–7
Reilly Jr JJ, Chen P, Sailor LZ, et al. Cigarette smoking induces an elastolytic cysteine proteinase in macrophages distinct from cathepsin L. Am J Physiol 1991; 261 (2 Pt 1): L41–8
Maestrelli P, Saetta M, Di Stefano A, et al. Comparison of leukocyte counts in sputum, bronchial biopsies, and bronchoalveolar lavage. Am J Respir Crit Care Med 1995; 152 (6 Pt 1): 1926–31
Brown DM, Brown GM, Macnee W, et al. Activated human peripheral blood neutrophils produce epithelial injury and fibronectin breakdown in vitro. Inflammation 1992; 16(1): 21–30
Segura-Valdez L, Pardo A, Gaxiola M, et al. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 2000; 117(3): 684–94
Finlay GA, O’Driscoll LR, Russell KJ, et al. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med 1997; 156(1): 240–7
Cataldo D, Munaut C, Noel A, et al. MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 2000; 123(3): 259–67
Bakowska J, Adamson IY. Collagenase and gelatinase activities in bronchoalveolar lavage fluids during bleomycin-induced lung injury. J Pathol 1998; 185(3): 319–23
Minematsu N, Nakamura H, Tateno H, et al. Genetic polymorphism in matrix metalloproteinase-9 and pulmonary emphysema. Biochem Biophys Res Commun 2001; 289(1): 116–9
Ofulue AF, Ko M, Abboud RT. Time course of neutrophil and macrophage elastinolytic activities in cigarette smoke-induced emphysema. Am J Physiol 1998; 275 (6 Pt 1): L1134–44
Imai K, Dalai SS, Chen ES, et al. Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. Am J Respir Crit Care Med 2001; 163 (3 Pt 1): 786–91
Cawston T, Billington C, Cleaver C, et al. The regulation of MMPs and TIMPs in cartilage turnover. Ann N Y Acad Sci 1999; 878: 120–9
Frankenberger M, Hauck RW, Frankenberger B, et al. All trans-retinoic acid selectively down-regulates matrix metalloproteinase-9 (MMP-9) and up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) in human bronchoalveolar lavage cells. Mol Med 2001; 7(4): 263–70
Acknowledgments
There was no financial support in the preparation of this manuscript and no conflicts of interest directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Suzuki, R., Miyazaki, Y., Takagi, K. et al. Matrix Metalloproteinases in the Pathogenesis of Asthma and COPD. Treat Respir Med 3, 17–27 (2004). https://doi.org/10.2165/00151829-200403010-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151829-200403010-00003